Treatment of Vasospasm of Aneurysmal Subarachnoid Hemorrhage With Intrathecal Nicardipine - FAST-IT Trial

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorThe Affiliated Hospital Of Guizhou Medical University

About this trial

To investigate whether patients with cerebral vasospasm associated with aneurysmal subarachnoid hemorrhage have a better prognosis with intrathecal nicardipine injection via extraventricular drainage or lumbar drainage.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 18-80.

Spontaneous SAH confirmed by head CT.

Saccular brain aneurysm is identified and treated, either surgically or endovascularly.

SAH Fisher grade >1 or modified Fisher grade >0.

Disqualifiers

Hunt-Hess Grade 5 or WFNS Grade 5 (no clinical improvement after EVD placement for acute hydrocephalus).

Bacterial or distal aneurysms without subarachnoid hemorrhage in the basal cisterns.

The treating physician determines that the culprit aneurysm has not been fully repaired, with a very high likelihood of rebleeding in the near term.

History of head trauma within the past 3 months.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Intrathecal Nicardipine

    Drug

    First, 6 ml of cerebrospinal fluid is withdrawn from the EVD or LD catheter, and then 4 ml (4mg) of nicardipine is injected into the EVD or LD drain tube, followed by 2 ml normal saline solution, and then the EVD or LD tube is clamped for 2 hours, and then kept open as clinically necessary until the next dose (q12h) of medication.

  • No intervention

    Other intervention

    A simulated "intrathecal administration" operation is performed by a dedicated physician who is unblinded to the group assignment, the EVD or LD tube is not opened, and no "drug" is given. The simulated administration process needs to be out of the patient's view (if awake patient) and out of the presence of study team personnel.

Treatment groups

396 Participants
are divided into 2 treatment groups
Group A: Intrathecal Treatment GroupExperimental treatment 1 intervention
Group B: Control GroupSham comparator 1 intervention

Trial outcomes

Primary outcomes

1

Dichotomized Modified Rankin Scale (mRS) 0-2 vs 3-6

The percentage of patients with mRS 0-2

Time frame
Day 90±30, Day 365±60.

Secondary outcomes

1

Extended Glasgow Outcome Score (GOS-E).

Minimum score 1 and maximum score 8 with higher number being better outcome

Time frame
Day 90±30, Day 365±60.
2

Modified Rankin Scale ordinal shift with mRS 5 and 6 combined

Shift analysis looks at transitions across different levels of mRS score, shifting from higher score to lower score means favorable outcome

Time frame
Day 90±30, Day 365±60.
3

Dichotomized Modified Rankin Scale (mRS) 0-3 vs 4-6

The percentage of patients with mRS 0-3

Time frame
Day 90±30, Day 365±60.
4

Mini-Mental State Examination (MMSE) score

Minimum score 0 and maximum score 30 with higher score being better outcome

Time frame
Day 90±30, Day 365±60.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.